| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Nectar Lifesciences Limited (NSE: NECLIFE)
NECLIFE Technical Analysis
1.5
| As on 30th Apr 2024 NECLIFE SHARE Price closed @ 34.45 and we RECOMMEND Buy for LONG-TERM with Stoploss of 28.06 & Sell for SHORT-TERM with Stoploss of 35.30 we also expect STOCK to react on Following IMPORTANT LEVELS. |
NECLIFESHARE Price
| Open | 34.80 | Change | Price | % |
| High | 34.80 | 1 Day | -0.15 | -0.43 |
| Low | 34.45 | 1 Week | 0.45 | 1.32 |
| Close | 34.45 | 1 Month | 4.30 | 14.26 |
| Volume | 100365 | 1 Year | 16.15 | 88.25 |
| 52 Week High 32.35 | 52 Week Low 14.65 | ||||
NSE INDIA Most Active Stocks
| IDEA | 13.20 | -1.86% |
| YESBANK | 26.15 | -3.51% |
| NHPC | 96.20 | 3.00% |
| PNB | 141.05 | 2.77% |
| IDFCFIRSTB | 82.15 | 0.61% |
| RECLTD | 507.15 | 9.54% |
| IOC | 168.85 | -4.47% |
| MAHABANK | 70.10 | -1.34% |
| HFCL | 100.50 | 2.60% |
| TATASTEEL | 165.00 | -1.43% |
NSE INDIA Top Gainers Stocks
| HISARMETAL | 222.00 | 20.00% |
| WILLAMAGOR | 40.95 | 19.91% |
| NGIL | 61.65 | 15.67% |
| LIKHITHA | 351.20 | 12.80% |
| COMPUSOFT | 36.45 | 11.98% |
| PDMJEPAPER | 83.50 | 11.71% |
| BFUTILITIE | 862.25 | 10.74% |
| POWERINDIA | 9578.75 | 10.53% |
| IRIS | 155.15 | 10.00% |
| HINDMOTORS | 34.65 | 10.00% |
NSE INDIA Top Losers Stocks
| NECLIFE Daily Charts |
NECLIFE Intraday Charts |
Whats New @ Bazaartrend |
NECLIFE Free Analysis |
|
|
NECLIFE Important Levels Intraday
| RESISTANCE | 35.12 |
| RESISTANCE | 34.91 |
| RESISTANCE | 34.77 |
| RESISTANCE | 34.64 |
| SUPPORT | 34.26 |
| SUPPORT | 34.13 |
| SUPPORT | 33.99 |
| SUPPORT | 33.78 |
NECLIFE Target May 2024
| 4th UP Target | 63.36 |
| 3rd UP Target | 54.99 |
| 2nd UP Target | 49.81 |
| 1st UP Target | 44.63 |
| 1st DOWN Target | 29.87 |
| 2nd DOWN Target | 24.69 |
| 3rd DOWN Target | 19.51 |
| 4th DOWN Target | 11.14 |
NECLIFE Weekly Target
| 4th UP Target | 42.18 |
| 3rd UP Target | 39.93 |
| 2nd UP Target | 38.53 |
| 1st UP Target | 37.14 |
| 1st DOWN Target | 33.16 |
| 2nd DOWN Target | 31.77 |
| 3rd DOWN Target | 30.37 |
| 4th DOWN Target | 28.12 |
NECLIFE Target2024
| 4th UP Target | 72.42 |
| 3rd UP Target | 59.51 |
| 2nd UP Target | 51.52 |
| 1st UP Target | 43.54 |
| 1st DOWN Target | 20.76 |
| 2nd DOWN Target | 12.78 |
| 3rd DOWN Target | 4.79 |
| 4th DOWN Target | -8.12 |
Nectar Lifesciences Limited ( NSE INDIA Symbol : NECLIFE )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
NECLIFE Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is Below 20 | Over Sold | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Long Buy | 9.75 | |
| 10 Day Avg Volume | Traded -12.99 % Less then 10 Day Average Volume | ||
NECLIFE Other Details
| Segment | EQ | |
| Market Capital | 6178390016.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
NECLIFE Address
 |
||
NECLIFE Latest News
NECLIFE Business Profile
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company offers contract research and manufacturing services, including process development and optimization, process scale up and validation, preparation and international submission of drug master files and certificates of suitability, multi kilo pilot plant production, bulk production, and chiral resolution; and chemical and analytical development, as well as analytical, manufacturing, and engineering consulting services. Its active pharmaceutical ingredients and intermediates comprise cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil, cefdinir, ceftriaxone sodium, cefotaxime sodium, cefuroxime sodium, ceftazidime, cefepime HCl, cephalothin, cefazolin sodium, cefprozil, cefoperzone sodium, cefpirome sulphate, and cefoxitin sodium. The company also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, it provides a range of diagnostics products; empty hard gelatin capsules; and menthol products. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India. Address: SCO 38-39, Chandigarh, India, 160009
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service